Pipeline

Project

Area

Mode of Action

Phase I

Phase II

Phase III

Filing 

Brexpiprazole*

Agitation in Alzheimer’s disease

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. Brexpiprazole acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors.

           

Brexpiprazole*

Post-Traumatic Stress Disorder

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. Brexpiprazole acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors.

 

      

     

 
Brexpiprazole* Borderline Personality Disorder

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. Brexpiprazole acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors.

           

Lu AF11167 (PDE 10 inhibitor)

Schizophrenia

Lu AF11167 is a small molecule and a potent and selective inhibitor of the phosphodiesterase 10A enzyme (PDE10Ai). Lu AF11167 modulates dopamine D1 and D2 receptor-mediated intraneuronal signaling without interacting with the receptors themselves.

 

      

   
Lu AG06466 (MAGLi)

Neurology/
Psychiatry

Lu AG06466 is a small molecule, orally active and highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing 2-AG levels is a viable approach to restore brain homeostasis.

               

Lu AF82422 (alpha-synuclein mAb)

 

Synucleinopathies

 

 

Lu AF82422 is a human antibody targeting alpha-synuclein. Extracellular alpha-synuclein is believed to play a major role in disease pathology and progression in Parkinson’s disease.

 

           
Lu AF28996 (D1/D2 agonist) Parkinson’s Disease Lu AF28996 is a small molecule which works through D1/D2 agonism. Both D1 and D2 dopamine receptor stimulation plays an important role in motor control of Parkinson’s Disease patients.            
Lu AF88434 (PDE1B inhibitor) Cognitive  dysfunction

Lu AF88434 is a small molecule and a potent and selective PDE1B phosphodiesterase inhibitor which increases neuronal levels of cyclic nucleotide messengers. Strengthening intracellular neuronal signaling by increasing neuronal levels of cyclic nucleotide messengers may result in enhanced neuroplasticity/intracellular signaling and cognitive functioning.

            
Lu AG09222 (PACAP mAb) Migraine

LU AG09222 (PACAP) is an early-stage monoclonal antibody (mAb) designed to inhibit pituitary adenylate cyclase-activating polypeptide for migraine prevention. PACAP has emerged as a signaling molecule in the pathophysiology of migraine.

            
Lu AF87908
(Tau mAb)
Tauopathies             Lu AF87908 (TAU mAb) is an antibody targeting the pathological form of the protein tau which is believed to play a pivotal role in the development and progression of Alzheimer’s disease and other neurodegenerative disorders.

 

      

 

   
Lu AG06466 (MAGLi) Neuropathic Pain Lu AG06466 is a small molecule, orally active and highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing 2-AG levels is a viable approach to restore brain homeostasis.            
Lu AF95245 (kv7 activator) Neuropsychiatric disorders

Lu AF95245 is a small molecule and a potent and selective potassium Kv7. 2-5 channel activator. Lu AF95245 reverses neuronal repetitive or burst firing.

           

* In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc. 

 

 

 

 

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.